Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study

References

• Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1999;352:837-53
   Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91
   PubMed Web of Science ®Google Scholar
• Gaede P, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008;31:1510-15
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008;358:2630-3
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008;31(Suppl 1):S12-54
   PubMed Web of Science ®Google Scholar
• Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42
   PubMed Web of Science ®Google Scholar
• Hatzitolios AI, Athyros VG, Karagiannis A, et al.; for the IMPROVE Collaborative Group. Implementation of strategy for the management of overt dyslipidemia: The IMPROVE-dyslipidemia study. Int J Cardiol 2009;134:322-9
   PubMed Web of Science ®Google Scholar
• Athyros VG, Karagiannis A, Hatzitolios AI, et al. Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. Curr Med Res Opin 2009;25:971-80
   PubMed Web of Science ®Google Scholar
• Karagiannis A, Hatzitolios AI, Athyros VG, et al.; for the IMPULSION Collaborative Group. IMPlementation of gUideLines for the management of arterial hypertenSION. The IMPULSION study. Open Cardiovasc Med J 2009 (in press)
   Google Scholar
• Expert Committee on the Diagnosis and the Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and the classification of diabetes mellitus. Diabetes Care 1997;20:1183-97
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Panagiotakos DB, Pitsavos C, Stefanadis C. Dietary patterns: a Mediterranean diet score and its relation to clinical and biological markers of cardiovascular disease risk. Nutr Metab Cardiovasc Dis 2006;16:559-68
   PubMed Web of Science ®Google Scholar
• Panagiotakos DB, Pitsavos C, Arvaniti F, et al. Adherence to the Mediterranean food pattern predicts the prevalence of hypertension, hypercholesterolemia, diabetes and obesity, among healthy adults; the accuracy of the MedDietScore. Prev Med 2007;44:335-40
   PubMed Web of Science ®Google Scholar
• Panagiotakos DB, Pitsavos C, Chrysohou C, et al. The effect of clinical characteristics and dietary habits on the relationship between education status and 5-year incidence of cardiovascular disease: the ATTICA study. Eur J Nutr 2008;47:258-65
   PubMed Web of Science ®Google Scholar
• Stevens R, Adler A, Gray A, et al. Life-expectancy projection by modelling and computer simulation (UKPDS 46). Diab Res Clin Pract 2000;50(Suppl 3):S5-13
   PubMedGoogle Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• The global challenge of diabetes (Editorial). Lancet 2008;371:1723
   Google Scholar
• Burns N, Finucane FM, Hatunic M, et al. Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. Diabetologia 2007;50:1500-8
   PubMed Web of Science ®Google Scholar
• Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don't diabetes patients achieve recommended risk factor targets^1? Poor adherence versus lack of treatment intensification. J Gen Intern Med 2008;23:588-94
   PubMed Web of Science ®Google Scholar
• Ford ES, Capewell S. Coronary heart disease mortality among young adults in the US from 1980 through 2002. Concealed leveling of mortality rates. J Am Coll Cardiol 2007;50:2128-32
   PubMed Web of Science ®Google Scholar
• Greenland P, Lloyd-Jones D. Time to end the mixed – and often incorrect – messages about prevention and treatment of atherosclerotic cardiovascular disease. J Am Coll Cardiol 2007;50:2133-5
   PubMed Web of Science ®Google Scholar
• O'Flaherty M, Ford E, Allender S, et al. Coronary heart disease trends in England and Wales from 1984 to 2004: concealed leveling of mortality rates among young adults. Heart 2008;94:178-81
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al; METS-GREECE Collaborative Group. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin 2004;20:1691-701
   PubMed Web of Science ®Google Scholar
• Zazpe I, Sanchez-Tainta A, Estruch R, et al. A large randomized individual and group intervention conducted by registered dietitians increased adherence to Mediterranean-type diets: the PREDIMED study. J Am Diet Assoc 2008;108:1134-44
   PubMed Web of Science ®Google Scholar
• Estruch R, Martínez-González MA, Corella D, et al.; PREDIMED Study Investigators. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006;145:1-11
   PubMed Web of Science ®Google Scholar
• Bellary S, O'Hare JP, Raymond NT, et al.; UKADS Study Group. Enhanced diabetes care to patients of south Asian ethnic origin (the United Kingdom Asian Diabetes Study): a cluster randomised controlled trial. Lancet 2008;371:1769-76
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
   Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes 2004;53(Suppl 3):S39-47
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, et al.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Symeonidis AN, et al.; GREACE Study Collaborative Group. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003;54:679-90
   PubMed Web of Science ®Google Scholar
• Hunsicker LG. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control. J Manag Care Pharm 2004;10(Suppl A):S12-17
   PubMedGoogle Scholar
• Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better^1?. Clin Ther 2007;29:1803-24
   PubMed Web of Science ®Google Scholar
• Tomita H, Kawamoto R, Tabara Y, et al. Blood pressure is the main determinant of the reflection wave in patients with type 2 diabetes. Hypertens Res 2008;31:493-9
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87:819-22
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, Guy De Backer G, et al.; for the EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40
   PubMed Web of Science ®Google Scholar
• Zannad F, Agabiti-Rosei E. Profile of patients with type 2 diabetes in France and Italy. J Hypertens 2008;26(Suppl 3):S3-6
   Google Scholar
• Ott P, Benke I, Stelzer J, et al. [“Diabetes in Germany” (DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice] [Article in German] Dtsch Med Wochenschr 2009;134:291-7
   PubMed Web of Science ®Google Scholar
• McDonald M, Hertz RP, Unger AN, et al. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci 2009;64:256-63
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Bhatt DL, Mehta S, et al. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J 2008;156:719-27
   PubMed Web of Science ®Google Scholar